C
Open Session Agendas
September 22, 2020
CLOSED SESSION
Full Schedule in Eastern Time
11:00–11:15 | Welcome GUY PALMER, Committee Chair |
11:15–12:45 | Bias and Conflict of Interest Discussion LAUREN SHERN, Director of Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine |
12:45–1:00 | Review Statement of Task and Study Timeline GUY PALMER, Committee Chair |
1:00–1:30 | Framing the Report for Policy Makers JULIE EUBANK, Assistant Director, Congressional and Government Affairs, National Academies of Sciences, Engineering, and Medicine |
1:30 | Adjourn |
September 23, 2020
OPEN SESSION
Full Schedule in Eastern Time
11:00–11:10 | Welcome GUY PALMER, Committee Chair |
11:10–11:50 | Sponsor Orientation to Statement of Task JANE KNISELY, Program Officer, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases (NIAID) |
11:50–12:15 | ASPE Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria AMANDA CASH, Director, Division of Evidence, Evaluation, and Data Policy, Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services |
12:15–12:40 | USDA Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria NEENA ANADARAMAN, Veterinary Science Policy Advisor, Office of the Chief Scientist, U.S. Department of Agriculture (USDA) |
12:40–1:05 | NIH Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria JANE KNISELY, Program Officer, Bacteriology and Mycology Branch, NIAID |
1:05–1:30 | BARDA Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria MARK ALBRECHT, Branch Chief, Anti-Bacterial Program, Division of CBRN Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) |
1:30 | Adjourn |
September 24, 2020
OPEN SESSION
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:30 | USAID Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria JESSICA PETRILLO, Senior Advisor for Antimicrobial Resistance and GHSA, Emerging Threats Division, Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development |
11:30–11:55 | FDA Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria WILLIAM FLYNN, Deputy Director for Science Policy, Center for Veterinary Medicine, Food and Drug Administration (FDA) |
11:55–12:20 | CDC Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria MICHAEL CRAIG, Senior Advisor for Antibiotic Resistance, Antibiotic Resistance Coordination and Strategy Unit, Centers for Disease Control and Prevention |
12:20–12:45 | Department of Defense Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria PAIGE WATERMAN, CARB Task Force Lead, Walter Reed Army Institute of Research, Department of Defense |
12:45–1:30 | Q&A |
1:30 | Adjourn |
September 25, 2020
CLOSED SESSION
Full Schedule in Eastern Time
11:00–1:30 | Closed session for committee deliberations. |
1:30 | Adjourn |
November 9, 2020
OPEN SESSION
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:35 | Additional Federal Actions Needed to Determine Magnitude and Reduce Impact of Antibiotic Resistance TIMOTHY PERSONS, Chief Scientist and Managing Director, Science, Technology Assessment, and Analytics, Government Accountability Office MARY DENIGAN-MACAULEY, Director, Health Care, Public Health & Private Markets, Government Accountability Office |
11:35–12:05 | Convergence in Antimicrobial Use and Factor Influencing Resistance RAMANAN LAXMINARAYAN, Director and Senior Fellow, Center for Disease Dynamics, Economics & Policy |
12:05–12:15 | Break |
12:15–12:45 | Measuring the Impacts of FDA’s Actions to Promote Judicious Antimicrobial Use in Veterinary Medicine SUSAN BRIGHT, Veterinary Medical Officer, Office of Surveillance & Compliance, Center for Veterinary Medicine, FDA |
12:45–1:15 | National Scale Monitoring of Antimicrobial Resistance in Surface Water JAY GARLAND, Senior Research Scientist, Office of Research and Development, Environmental Protection Agency |
1:15–1:45 | International Activities in AMR, Department of Health and Human Services LYNN FILPI, AMR Team Lead, Senior Global Health Officer, Pandemic and Emerging Threat Office, Office of Global Affairs, HHS |
1:45–2:00 | Closing Questions |
2:00 | Adjourn |
November 10, 2020
OPEN SESSION
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:35 | Monitoring Countries’ Progress on Tripartite Global Action Plan ANAND BALACHANDRAN, Unit Head, AMR National Action Plans and Monitoring & Evaluation, AMR Division, World Health Organization (WHO) Headquarters |
11:35–12:05 | The Norwegian National Strategy Against Antibiotic Resistance GUNNAR SKOV SIMONSEN, Professor of Clinical Microbiology, University of Tromsø; Director of the Department of Microbiology and Infection Control, University Hospital of North Norway |
12:05–12:15 | Break |
12:15–12:45 | Antibiotic Resistance in the Food Chain FRANK MØLLER AARESTRUP, Professor, Head of Division, Division for Global Surveillance, Research Group for Genomic Epidemiology, National Food Institute, Technical University of Denmark |
12:45–1:15 | Antimicrobial Use in Companion Animals MARK PAPICH, Professor of Clinical Pharmacology, Burroughs Wellcome Fund Professorship in Veterinary Pharmacology, College of Veterinary Medicine, North Carolina State University |
1:15–1:45 | Antimicrobial Use in Chilean Aquaculture FELIPE C. CABELLO, Professor Emeritus, Department of Microbiology and Immunology, New York Medical College |
1:45–2:00 | Closing Questions |
2:00 | Adjourn |
November 11, 2020
OPEN SESSION
Full Schedule in Eastern Time
11:00–11:05 | Welcome Guy Palmer, Committee Chair |
11:05–11:35 | The Global Antibiotic-Resistance Surveillance System CARMEM L PESSOA-SILVA, Unit Head—Surveillance, Evidence and Laboratory Strengthening, AMR Division, WHO |
11:35–12:05 | Shaping Strategies for Prevention and Response to Antibiotic Resistance TIM JINKS, Head Drug-Resistant Infections Priority Program, Wellcome Trust |
12:05–12:15 | Break |
12:15–12:45 | The Fleming Fund Support for AMR Surveillance TOM PILCHER, Head of Country Coordination, The Fleming Fund, Department of Health and Social Care CLAIRE GORDON, Lead Clinical Microbiologist, Mott MacDonald/The Fleming Fund |
12:45–1:15 | The Bill & Melinda Gates Foundation’s Strategy in AMR PADMINI SRIKANTIAH, Senior Program Officer, Global Health Antimicrobial Resistance Strategy Lead, Bill & Melinda Gates Foundation |
1:45–2:00 | Questions and Discussion |
2:00 | Adjourn |
November 13, 2020
CLOSED SESSION
Full Schedule in Eastern Time
11:00–12:30 | Debrief on Presentations GUY PALMER, Committee Chair |
12:30–1:30 | Next Steps GUY PALMER, Committee Chair |
1:30 | Adjourn |
January 5, 2021
OPEN SESSION
The Antimicrobial Product Pipeline and Incentives for Market Viability
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:30 | The Post-Approval Challenges of Antimicrobial Development KEVIN KRAUSE, Vice President, Clinical Science and Development Operations, AN2 Therapeutics Inc. |
11:30–11:55 | Pricing of Antibiotics and Proposals to Strengthen the Pipeline JOHN REX, Chief Medical Officer and Director, F2G, Ltd.; Editor-in-Chief, AMR Solutions; Operating Partner, Advent Life Sciences |
12:00–12:15 | Break |
12:15–1:45 | Panel Discussion on Push and Pull Incentives LEFTERIS MYLONAKIS, Moderator WES KIM, Senior Officer, Antibiotic Resistance Project, The Pew Charitable Trusts KEVIN OUTTERSON, Executive Director, Combating Antibiotic-Bacteria Biopharmaceutical Accelerator RYAN CIRZ, CSO and Acting Chief Executive Officer, Revagenix, Inc. MARK ALBRECHT, Branch Chief, Anti-Bacterial Program, Division of CBRN Countermeasures, BARDA |
1:45–2:10 | Championing Patient and Public Health Needs: IDSA Efforts to Strengthen the Antibiotic Pipeline HELEN BOUCHER, Chief, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center Director, Levy Center for Integrated Management of Antimicrobial Resistance Treasurer, Infectious Diseases Society of America |
2:10–2:35 | A New, Sustainable Model for Antibiotic R&D BRAD SPELLBERG, Chief Medical Officer, Los Angeles County-University of Southern California Medical Center |
2:45 | Adjourn |
January 6, 2021
OPEN SESSION
Diagnostics and Susceptibility Testing
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:30 | The Relationship Between Antimicrobial Susceptibility Testing Devices and Antibiotic Markets KEVIN KRAUSE, Vice President, Clinical Science and Development Operations, AN2 Therapeutics Inc. |
11:30–11:55 | Regulatory Challenges in Antimicrobial Diagnostics BARBARA ZIMMER, Principal Scientist, Microbiology Scientific Affairs, Beckman Coulter, Inc. |
11:55–1:15 | Diagnostics Panel Discussion JENN DIEN BARD, Moderator MARK MILLER, Chief Medical Officer, bioMerieux FRED C. TENOVER, Vice President, Scientific Affairs, Cepheid ANGELA CALIENDO, Warren Alpert Foundation Professor of Medicine, Executive Vice Chair of Medicine, Alpert Medical School, Brown University BARBARA ZIMMER, Principal Scientist, Microbiology Scientific Affairs, Beckman Coulter, Inc. |
1:15–1:30 | Break |
1:30–1:50 | VetCAST Susceptibility Test Breakpoints PETER PANDURO DAMBORG, Associate Professor, Veterinary Clinical Microbiology, University of Copenhagen |
1:50–2:10 | Addressing Challenges in Veterinary Diagnostics BRIAN LUBBERS, Associate Professor, College of Veterinary Medicine, Kansas State University |
2:10–2:45 | Discussion on Veterinary Diagnostics and Susceptibility Test Breakpoints EMMANUEL OKELLO, Moderator PETER PANDURO DAMBORG, Associate Professor, Veterinary Clinical Microbiology, University of Copenhagen BRIAN LUBBERS, Associate Professor, College of Veterinary Medicine, Kansas State University |
2:45 | Adjourn |
January 7, 2021
OPEN SESSION
Antimicrobial Stewardship
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:30 | Telehealth and Antimicrobial Stewardship JOHN LYNCH, Associate Medical Director, Harborview Medical Center Antimicrobial Stewardship Program; Associate Professor, Division of Allergy and Infectious Diseases, University of Washington School of Medicine |
11:30–11:55 | Antimicrobial Stewardship in Remote Areas MARC MENDELSON, Professor of Infectious Disease, Division of Infectious Diseases & HIV Medicine, University of Cape Town |
11:55–12:20 | Antimicrobial Stewardship in Nursing Homes: Barriers and Opportunities CHRIS CRNICH, Chief of Medicine, Madison VA Hospital; Associate Professor of Medicine, Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health |
12:20–12:35 | Break |
12:35–1:00 | The Road to Research and Development of Alternatives to Antibiotics in the United States CYRIL GAY, Senior National Program Leader, Animal Production and Protection, Agricultural Research Service, USDA |
1:00–2:30 | Panel Discussion on Incentives for Stewardship in Agribusiness MARTA GOMEZ-CHIARRI, Moderator BRUCE STEWART-BROWN, Senior Vice-President of Food Safety, Quality, and Live Operations, Perdue Foods BILL KELEHER, President and Chief Executive Officer, Kennebec River Biosciences CRAIG WILSON, Vice President, GMM, Costco Wholesale HEATHER FOWLER, Director of Producer and Public Health, National Pork Board |
2:30 | Adjourn |
January 8, 2021
OPEN SESSION
Full Schedule in Eastern Time
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:35 | Anthropology of Antimicrobial Resistance CLARE CHANDLER, Professor in Medical Anthropology; Director, London School of Hygiene & Tropical Medicine |
11:35–12:05 | The Global Burden of Antimicrobial Resistance CHRIS MURRAY, Director, Institute for Health Metrics and Evaluation; Chair and Professor, Health Metrics Sciences, University of Washington |
12:05 | Open Session Adjourn |
CLOSED SESSION
Full Schedule in Eastern Time
12:05–12:20 | Break |
12:20–1:20 | Debrief GUY PALMER, Committee Chair |
1:20–2:00 | Next Steps GUY PALMER, Committee Chair |
2:00 | Adjourn |
March 16, 2021
OPEN SESSION
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:35 | GARDP and Antimicrobial Development MANICA BALASEGARAM, Executive Director, Global Antibiotic R&D Partnership JENNIFER SCHNEIDER, Senior Advisor External Affairs, Global Antibiotic R&D Partnership |
11:35–12:05 | Inpatient Reimbursement and the Antimicrobial Market ANAND SHAH, former Deputy Commissioner for Medical and Scientific Affairs, FDA |
12:05 | Adjourn Open Session |
March 16, 2021
CLOSED SESSION
12:15–12:30 | Overview Draft Recommendations, Guidance on Writing Recommendations |
12:30–3:00 | Discussion of Draft Recommendations and Conclusions in Stewardship and Prevention |
3:00 | Adjourn |
March 17, 2021
CLOSED SESSION
11:00–12:00 | Discussion of Draft Recommendations and Conclusions on Push and Pull Incentives |
12:00–12:15 | Break |
12:15–2:45 | Discussion of Draft Recommendations and Conclusions on Diagnostics and Related Questions |
2:45 | Adjourn |
March 18, 2021
CLOSED SESSION
11:00–12:00 | Discussion of Draft Recommendations and Conclusions on International Action |
12:00–12:15 | Break |
12:15–2:00 | Discussion Draft Recommendations and Conclusions on Health and Economic Burden |
2:00 | Adjourn |
March 19, 2021
OPEN SESSION
11:00–11:05 | Welcome GUY PALMER, Committee Chair |
11:05–11:45 | Direct, Predictive Application of Sequencing and Informatics GAUTAM DANTAS, Professor, Washington University School of Medicine |
11:45 | Adjourn Open Session |
March 19, 2021
CLOSED SESSION
12:00–1:00 | Discussion of Draft Recommendations and Conclusions on Surveillance |
1:00 | Adjourn |
May 11, 2021
CLOSED SESSION
11:00–2:00 | Deliberation on Report Recommendations |
2:00 | Adjourn |
May 12, 2021
CLOSED SESSION
11:00–12:15 | Deliberation on Report Recommendations |
12:15–12:30 | Break |
May 12, 2021
OPEN SESSION
12:30–1:30 | Agencies’ Progress on National Action Plan, Mixed Methods Analysis KRIS MOORE, Medical Director, Center for Infectious Disease Research and Policy, University of Minnesota |
1:30 | End Open Session |
May 12, 2021
CLOSED SESSION
1:30 | Debrief on Presentation |
2:00 | Adjourn |
May 13, 2021
CLOSED SESSION
11:00–2:00 | Deliberation on Report Recommendations |
2:00 | Adjourn |
May 14, 2021
CLOSED SESSION
11:00–2:00 | Deliberation on Report Recommendations |
2:00 | Adjourn |
This page intentionally left blank.